42Author name et al. / Engineering 2(2016) xxx–xxx [83] Woerdenbag HJ, Moskal TA, Pras N, Malingré TM, el-Feraly FS, Kampinga HH, et al. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J Nat Prod 1993;56(6):849–56. [84] Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 1995;91(1):41–6. [85] Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001;18(4):767–73. [86] Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003;64(2):382–94. [87] Zhang ZY, Yu SQ, Miao LY, Huang XY, Zhang XP, Zhu YP, et al. Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial. J Chin Integr Med 2008;6 (2):134–8. [88] Jansen FH, Adoubi I, JC KC, DE Cnodder T, Jansen N, Tschulakow A, et al. First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. Anticancer Res 2011;31(12):4417–22. [89] Krishna S, Ganapathi S, Ster IC, Saeed ME, Cowan M, Finlayson C, et al. A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine 2014;2(1):82–90. [90] Efferth T, Rücker G, Falkenberg M, Manns D, Olbrich A, Fabry U, et al. Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung 1996;46(2):196–200. [91] Willoughby JA Sr, Sundar SN, Cheung M, Tin AS, Modiano J, Firestone GL. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 2009;284 (4):2203–13. [92] Steinbrück L, Pereira G, Efferth T. Effects of artesunate on cytokinesis and G2/M cell cycle progression of tumour cells and budding yeast. Cancer Genomics Proteomics 2010;7(6):337–46. [93] Hamacher-Brady A, Stein HA, Turschner S, Toegel I, Mora R, Jennewein N, et al. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem 2011;286(8):6587–601. [94] Anfosso L, Efferth T, Albini A, Pfeffer U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J 2006;6(4):269–78. [95] Button RW, Lin F, Ercolano E, Vincent JH, Hu B, Hanemann CO, et al. Artesunate induces necrotic cell death in schwannoma cells. Cell Death Dis 2014;5:e1466. [96] Buommino E, Baroni A, Canozo N, Petrazzuolo M, Nicoletti R, Vozza A, et al. Artemisinin reduces human melanoma cell migration by down-regulating αVβ3 integrin and reducing metalloproteinase 2 production. Invest New Drugs 2009;27(5):412–8. [97] Chen T, Li M, Zhang R, Wang H. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 2009;13(7):1358–70. [98] Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 2008;68(11):4347–51. [99] Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008;14(17):5519–30. [100] Berdelle N, Nikolova T, Quiros S, Efferth T, Kaina B. Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ ATR damage response in cancer cells. Mol Cancer Ther 2011;10(12):2224–33. [101] Huang C, Ba Q, Yue Q, Li J, Li J, Chu R, et al. Artemisinin rewires the protein interaction network in cancer cells: network analysis, pathway identification, and target prediction. Mol Biosyst 2013;9(12):3091–100. [102] Li X, Ba Q, Liu Y, Yue Q, Chen P, Li J, et al. Dihydroartemisinin selectively inhibits PDGFR a-positive ovarian cancer growth and metastasis through inducing degradation of PDGFR α protein. Cell Discov 2017;3:17042. [103] Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 2004;37(7):998–1009. [104] Ba Q, Zhou N, Duan J, Chen T, Hao M, Yang X, et al. Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor- 1. PLoS One 2012;7(8):e42703. [105] Zhang S, Gerhard GS. Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. PLoS One 2009;4(10):e7472. [106] Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul W, et al. Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer 2009;125(6):1266–75. [107] Zhang S, Chen H, Gerhard GS. Heme synthesis increases artemisinin-induced radical formation and cytotoxicity that can be suppressed by superoxide scavengers. Chem Biol Interact 2010;186(1):30–5. [108] Mercer AE, Copple IM, Maggs JL, O’Neill PM, Park BK. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem 2011;286 (2):987–96. [109] Hooda J, Cadinu D, Alam MM, Shah A, Cao TM, Sullivan LA, et al. Enhanced heme function and mitochondrial respiration promote the progression of lung cancer cells. PLoS One 2013;8(5):e63402. [110] Hooda J, Shah A, Zhang L. Heme, an essential nutrient from dietary proteins, critically impacts diverse physiological and pathological processes. Nutrients 2014;6(3):1080–102. [111] Hooda J, Alam M, Zhang L. Measurement of heme synthesis levels in mammalian cells. J Vis Exp 2015;101:e51579. [112] Zhang X, Ba Q, Gu Z, Guo D, Zhou Y, Xu Y, et al. Fluorescent coumarinartemisinin conjugates as mitochondria-targeting theranostic probes for enhanced anticancer activities. Chemistry 2015;21(48):17415–21. [113] Zhang CJ, Wang J, Zhang J, Lee YM, Feng G, Lim TK, et al. Mechanism-guided design and synthesis of a mitochondria-targeting artemisinin analogue with enhanced anticancer activity. Angew Chem Int Ed 2016;55(44):13770–4. [114] Wang J, Zhang J, Shi Y, Xu C, Zhang C, Wong YK, et al. Mechanistic investigation of the specific anticancer property of artemisinin and its combination with aminolevulinic acid for enhanced anticolorectal cancer activity. ACS Cent Sci 2017;3(7):743–50. [115] Wong YK, Xu C, Kalesh KA, He Y, Lin Q, Wong WSF, et al. Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action. Med Res Rev 2017;37(6):1492–517. [116] Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149(5):1060–72. [117] Eling N, Reuter L, Hazin J, Hamacher-Brady A, Brady NR. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2015;2(5):517–32. [118] Ooko E, Saeed ME, Kadioglu O, Sarvi S, Colak M, Elmasaoudi K, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine 2015;22(11):1045–54. [119] Yang ND, Tan SH, Ng S, Shi Y, Zhou J, Tan KS, et al. Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J Biol Chem 2014;289(48):33425–41. [120] Efferth T. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. Semin Cancer Biol 2017;46:65–83. [121] Abba ML, Patil N, Leupold JH, Saeed MEM, Efferth T, Allgayer H. Prevention of carcinogenesis and metastasis by artemisinin-type drugs. Cancer Lett 2018;429:11–8. [122] Noori S, Hassan ZM. Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo. Cell Immunol 2011;271 (1):67–72. [123] Farsam V, Hassan ZM, Zavaran-Hosseini A, Noori S, Mahdavi M, Ranjbar M. Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+CD25+FoxP3+ T reg cells in vivo. Int Immunopharmacol 2011;11(11):1802–8. [124] Zhang LX, Liu ZN, Ye J, Sha M, Qian H, Bu XH, et al. Artesunate exerts an antiimmunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression. Cell Biol Int 2014;38(5):639–46. [125] Cui C, Feng H, Shi X, Wang Y, Feng Z, Liu J, et al. Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor β1 and interleukin-10. Int Immunopharmacol 2015;27(1):110–21. [126] Reiter C, Fr?hlich T, Gruber L, Hutterer C, Marschall M, Voigtl?nder C, et al. Highly potent artemisinin-derived dimers and trimers: synthesis and evaluation of their antimalarial, antileukemia and antiviral activities. Bioorg Med Chem 2015;23(17):5452–8. [127] Fr?hlich T, ?apc? Karag?z A, Reiter C, Tsogoeva SB. Artemisinin-derived dimers: potent antimalarial and anticancer agents. J Med Chem 2016;59 (16):7360–88. [128] Fr?hlich T, Ndreshkjana B, Muenzner JK, Reiter C, Hofmeister E, Mederer S, et al. Synthesis of novel hybrids of thymoquinone and artemisinin with high activity and selectivity against colon cancer. ChemMedChem 2017;12 (3):226–34. [129] Efferth T. Cancer combination therapies with artemisinin-type drugs. Biochem Pharmacol 2017;139:56–70. [130] Fr?hlich T, Hahn F, Belmudes L, Leidenberger M, Friedrich O, Kappes B, et al. Synthesis of artemisinin-derived dimers, trimers and dendrimers: investigation of their antimalarial and antiviral activities including putative mechanisms of action. Chemistry 2018;24(32):8103–13. [131] Horwedel C, Tsogoeva SB, Wei S, Efferth T. Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells. J Med Chem 2010;53(13):4842–8. [132] Reiter C, Herrmann A, ?apci A, Efferth T, Tsogoeva SB. New artesunic acid homodimers: potent reversal agents of multidrug resistance in leukemia cells. Bioorg Med Chem 2012;20(18):5637–41. [133] Reiter C, Capc? Karag?z A, Fr?hlich T, Klein V, Zeino M, Viertel K, et al. Synthesis and study of cytotoxic activity of 1,2,4-trioxane- and egonolderived hybrid molecules against Plasmodium falciparum and multidrugresistant human leukemia cells. Eur J Med Chem 2014;75:403–12. [134] Reiter C, Fr?hlich T, Zeino M, Marschall M, Bahsi H, Leidenberger M, et al. New efficient artemisinin derived agents against human leukemia cells, human cytomegalovirus and Plasmodium falciparum: 2nd generation 1,2,4- trioxane-ferrocene hybrids. Eur J Med Chem 2015;97:164–72. [135] Leto I, Coronnello M, Righeschi C, Bergonzi MC, Mini E, Bilia AR. Enhanced efficacy of artemisinin loaded in transferrin-conjugated liposomes versus stealth liposomes against HCT-8 colon cancer cells. ChemMedChem 2016;11 (16):1745–51. [136] Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T. Clinical trial Author name et al. / Engineering 2(2016) xxx–xxxof artesunate and artemether on multidrug resistant falciparum malaria in Thailand. A preliminary report. Southeast Asian J Trop Med Public Health 1991;22(3):380–5. [137] Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008;47 (6):804–11. [138] Keiser J, Utzinger J. Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr Opin Infect Dis 2007;20(6):605–12. [139] Saeed MEM, Krishna S, Greten HJ, Kremsner PG, Efferth T. Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacol Res 2016;110:216–26. [140] LamNS, Long X, SuXZ, LuF.Artemisinin and its derivatives intreatinghelminthic infections beyond schistosomiasis. Pharmacol Res 2018;133:77–100. [141] Efferth T. Beyond malaria: the inhibition of viruses by artemisinin-type 43compounds. Biotechnol Adv 2018;36(6):1730–7. [142] Li J, Casteels T, Frogne T, Ingvorsen C, Honoré C, Courtney M, et al. Artemisinins target GABAA receptor signaling and impair α cell identity. Cell 2017;168(1–2):86–100.e15. [143] Van der Meulen T, Lee S, Noordeloos E, Donaldson CJ, Adams MW, Noguchi GM, et al. Artemether does not turn α cells into β cells. Cell Metab 2018;27 (1). 218 25.e4. [144] Ho WE, Cheng C, Peh HY, Xu F, Tannenbaum SR, Ong CN, et al. Anti-malarial drug artesunate ameliorates oxidative lung damage in experimental allergic asthma. Free Radic Biol Med 2012;53(3):498–507. [145] Isacchi B, Arrigucci S, la Marca G, Bergonzi MC, Vannucchi MG, Novelli A, et al. Conventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in mice. J Liposome Res 2011;21(3):237–44.
青蒿素 - 一种从中药中发现的神奇药物 - 图文
